BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer
Methylation of the BRCA1 promoter is an epigenetic gene expression regulator and is frequently observed in ovarian cancer; however, conversion of methylation status is thought to drive disease recurrence. Therefore, longitudinal monitoring of methylation status by liquid biopsy in cell‐free DNA may...
Guardado en:
Autores principales: | Maha Elazezy, Katharina Prieske, Lan Kluwe, Leticia Oliveira‐Ferrer, Sven Peine, Volkmar Müller, Linn Woelber, Barbara Schmalfeldt, Klaus Pantel, Simon A. Joosse |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d5b14d9287144f21a36580691214ee91 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact
por: Natasha Honoré, et al.
Publicado: (2021) -
Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer
por: Veldore VH, et al.
Publicado: (2018) -
Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
por: Lionel Larribère, et al.
Publicado: (2021) -
DNA methylation profile in diffuse type gastric cancer: evidence for hypermethylation of the BRCA1 promoter region in early-onset gastric carcinogenesis
por: BERNAL,CAROLINA, et al.
Publicado: (2008) -
Rational Development of Liquid Biopsy Analysis in Renal Cell Carcinoma
por: Kate I. Glennon, et al.
Publicado: (2021)